AdipoGen Life Sciences

Boceprevir

CHF 80.00
In stock
AG-CR1-3735-M0055 mgCHF 80.00
AG-CR1-3735-M01010 mgCHF 120.00
AG-CR1-3735-M05050 mgCHF 250.00
More Information
Product Details
Synonyms Victrelis; EBP 520; SCH 503034
Product Type Chemical
Properties
Formula

C27H45N5O5

MW 519.7
CAS 394730-60-0
Purity Chemicals ≥95% (NMR)
Appearance White to off-white solid.
Solubility Soluble in DMSO (15mg/ml), ethanol (20mg/ml) or DMF (20mg/ml).
Identity Determined by 1H-NMR.
InChi Key LHHCSNFAOIFYRV-DOVBMPENSA-N
Smiles [H][C@]1(C2(C)C)[C@]2([H])CN(C([C@H](C(C)(C)C)NC(NC(C)(C)C)=O)=O)[C@]1([H])C(NC(CC3CCC3)C(C(N)=O)=O)=O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description
  • The antiviral agent boceprevir is a protease inhibitor that covalently and reversibly binds to the catalytic site (Ser139) of hepatitis C virus (HCV) nonstructural protein 3/4A (NS3/4A), a serine protease that is essential for viral replication (Ki = 14nM) by cleaving the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B. It inhibits the NS3/4A protease in an in vitro HCV replicon system with an EC50 value of 200 nM.
  • Boceprevir has been identified as a potential inhibitor of SARS-CoV-2 responsible for COVID-19. It inhibits SARS-CoV-2 viral replication by targeting the viral main protease Mpro (IC50 = 4.13µM).
Product References
  1. SCH 503034, a mechanism-based inhibitor of Hepatitis C Virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells: B.A. Malcolm, et al.; Antimicrob. Agents Chemother. 50, 1013 (2006)
  2. Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections: S. Venkatraman; Trends Pharmacol. Sci. 33, 289 (2012) (Review)
  3. The Discovery and Development of Boceprevir: A Novel, First-generation Inhibitor of the Hepatitis C Virus NS3/4A Serine Protease: A.Y. Howe & S. Venkatraman; J. Clin. Transl. Hepatol. 1, 22 (2013) (Review)
  4. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease: C. Ma, et al.; bioRxiv (Preprint) (2020)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.